For the quarter ending 2026-03-31, ALLR had $15,183K increase in cash & cash equivalents over the period. -$4,557K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,750 | -3,373 | -2,806 | -5,052 |
| Depreciation and amortization | -26 | 8 | -44 | 23 |
| Deferred income taxes | - | 0 | 0 | 0 |
| Intangible asset impairment | - | 0 | 0 | - |
| Common stock issued for services | - | -100 | -50 | -50 |
| Stock-based compensation | 160 | 47 | 132 | 303 |
| Unrealized foreign exchange gains | 0 | -1,251 | 0 | 13 |
| Non-cash interest expense | 96 | 19 | 74 | 92 |
| Change in fair value of warrant and derivative liabilities | 0 | 0 | 0 | -1 |
| Other current assets | -157 | 152 | -3 | 1 |
| Unearned revenue | - | 0 | - | - |
| Tax credit receivable | 216 | -796 | 53 | 839 |
| Prepaid expenses | 1,391 | 314 | 439 | 850 |
| Accounts payable | -47 | -1,572 | -3 | 436 |
| Accrued expenses and other liabilities | -476 | -53 | -324 | -2,322 |
| Income taxes payable | 0 | 0 | 0 | 7 |
| Net cash used in operating activities | -4,493 | -3,243 | -3,410 | -8,167 |
| Proceeds from issuance of convertible redeemable series a preferred stock | - | 0 | 0 | - |
| Purchase of property and equipment | 64 | 8 | - | - |
| Redemption of convertible redeemable series a preferred stock | - | 0 | 0 | - |
| Net cash used in investing activities | -64 | -8 | - | - |
| Proceeds from convertible promissory notes and accrued interest, net of discount | - | - | 0 | 0 |
| Proceeds from 3i promissory notes | - | 0 | - | - |
| Repayment of 3i debt | - | 0 | 0 | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | 0 | 0 | 0 | 11,143 |
| Net proceeds from sale of common stock and pre-funded warrant issuance | 2 | 244 | 2,451 | - |
| Proceeds from promissory notes | 20,000 | - | - | - |
| Common stock repurchase | 262 | 484 | 141 | 2,565 |
| Net cash provided by financing activities | 19,740 | -240 | 2,310 | 8,578 |
| Net increase in cash and cash equivalents | 15,183 | -3,491 | -1,100 | 411 |
| Effect of exchange rate changes on cash and cash equivalents | 1,891 | - | -1,949 | - |
| Cash, cash equivalents, and restricted cash, beginning of period | 14,687 | 16,895 | 19,533 | - |
| Cash, cash equivalents, and restricted cash, end of period | 29,812 | 14,687 | 16,895 | - |
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)